PHOENIX MOLECULAR IMAGING
🇺🇸United States
Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
Phase 2
Withdrawn
- Conditions
- Gliomas
- Interventions
- Drug: Sodium Acetate C11 PET/CT Imaging
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Phoenix Molecular Imaging
- Registration Number
- NCT01961934
- Locations
- 🇺🇸
Phoenix Molecular Imaging, Phoenix, Arizona, United States
C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma
Phase 2
Completed
- Conditions
- Prostate CancerProstate Adenocarcinoma
- Interventions
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Phoenix Molecular Imaging
- Target Recruit Count
- 300
- Registration Number
- NCT01530269
- Locations
- 🇺🇸
Phoenix Molecular Imaging, Phoenix, Arizona, United States
PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Phoenix Molecular Imaging
- Target Recruit Count
- 2000
- Registration Number
- NCT01304485
- Locations
- 🇺🇸
Phoenix Molecular Imaging, Phoenix, Arizona, United States
News
No news found